Updated survival and safety results from the phase 2 study (ANNIE) of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer
GYNECOLOGIC ONCOLOGY（2023）
摘要
To evaluate the activity of niraparib combined with anlotinib in patients with advanced platinum-resistant recurrent ovarian carcinoma.
更多查看译文
关键词
anlotinib,niraparib,dual therapy evaluation,platinum-resistant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要